Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells

Samankaltaisia teoksia

• Antibody-dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells
  Tekijä: Boyerinas, Benjamin, et al.
  Julkaistu: (2015)
• Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
  Tekijä: Donahue, Renee N., et al.
  Julkaistu: (2017)
• A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses
  Tekijä: Grenga, Italia, et al.
  Julkaistu: (2016)
• Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
  Tekijä: Grenga, Italia, et al.
  Julkaistu: (2015)
• Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
  Tekijä: Lepone, Lauren M., et al.
  Julkaistu: (2016)